3.505
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Agenus Inc Borsa (AGEN) Ultime notizie
Peptide Cancer Vaccine Market Set to Witness Significant Growth - openPR.com
Agenus (AGEN) Registers Plan to Offer 165,000 Common Shares | AG - GuruFocus
Analyst Reiterates Neutral Rating for Agenus (AGEN) | AGEN Stock News - GuruFocus
Agenus (AGEN) Target Price Raised by Analyst Baird | AGEN Stock News - GuruFocus
Agenus (AGEN) Receives Price Target Increase from Baird | AGEN S - GuruFocus
Agenus Inc. (NASDAQ:AGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Agenus names Dr Richard Goldberg as CDO - Medical Buyer
Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges - Yahoo Finance
Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Mo - GuruFocus
Agenus Inc. Reports Q1 2025 Progress and Financials - TipRanks
Agenus Inc. Earnings Call: Optimism Amid Challenges - TipRanks
Agenus signals near-term strategic transactions and operational cash burn target below $50M amid BOT/BAL data advances - MSN
Agenus (AGEN) Moves to Sell 165,000 Shares of Common Stock - GuruFocus
Agenus: Q1 Earnings Snapshot - MySA
Agenus appoints oncology veteran Dr. Goldberg as CDO By Investing.com - Investing.com Canada
Agenus (AGEN) Sets Strategic Path with New Leadership and Transactions - GuruFocus
Transcript : Agenus Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Agenus reports Q1 EPS ($1.03), consensus ($1.98) - TipRanks
Earnings call transcript: Agenus reports Q1 2025 net loss, stock rises premarket - Investing.com
Agenus (AGEN) Reports Strong Q1 Revenue Surpassing Expectations - GuruFocus
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer | AGEN Stock News - GuruFocus
Agenus (AGEN) Reports Q1 Earnings, Beats EPS Estimates - GuruFocus
Agenus Inc (AGEN) Q1 2025 Earnings: EPS Beats Estimates at -$1.0 - GuruFocus
Agenus Reports Q1 2025 Financial Results and Key Business Updates | AGEN Stock News - GuruFocus
AGEN Welcomes Renowned Cancer Expert Dr. Richard Goldberg as Chi - GuruFocus
Dr. Richard Goldberg Joins Agenus as Chief Development Officer - citybiz
Renowned Gi Oncology Leader Dr. Richard Goldberg Joins Agenus As Chief Development Officer - marketscreener.com
Agenus Reports Q1 2025 Financial Results and Key Business Updates - Stock Titan
Agenus appoints oncology veteran Dr. Goldberg as CDO - Investing.com
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer - Eagle-Tribune
Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
Agenus (AGEN) Set for Q1 Earnings Release with Optimistic EPS Re - GuruFocus
Agenus Inc (AGEN) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Agenus (AGEN) Set for Q1 Earnings Release with Optimistic EPS Revisions - GuruFocus
Lost Money on Agenus Inc. (AGEN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Investors Who Lost Money on Agenus Inc. (AGEN) Should Contact Levi & Korsinsky About Pending Class ActionAGEN - ACCESS Newswire
Peptide Cancer Vaccine Market Is Booming Worldwide | Marker - openPR.com
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report | AGEN Stock News - GuruFocus
Agenus To Provide Corporate Update And First Quarter 2025 Financial Report - marketscreener.com
Agenus to Reveal Q1 2025 Financial Performance and Strategic Updates: Key Details for Investors - Stock Titan
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report - Bluefield Daily Telegraph
Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Stu - GuruFocus
Breakthrough: Agenus BOT/BAL Cancer Treatment Achieves 90% Response Rate Across Multiple Tumors - Stock Titan
AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):